Q32 Bio Inc.
QTTB
$1.60
-$0.085-5.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -224.35% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -224.35% | -- | -- | -- |
| Cost of Revenue | 51.73% | 41.00% | -- | -- | -- |
| Gross Profit | -25.44% | -191.50% | -- | -- | -- |
| SG&A Expenses | 81.86% | 75.44% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.88% | 48.82% | -- | -- | -- |
| Operating Income | -36.98% | -154.92% | -- | -- | -- |
| Income Before Tax | 10.69% | -61.88% | -- | -- | -- |
| Income Tax Expenses | -93.40% | 2,190.24% | -- | -- | -- |
| Earnings from Continuing Operations | 11.18% | -66.68% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.18% | -66.68% | -- | -- | -- |
| EBIT | -36.98% | -154.92% | -- | -- | -- |
| EBITDA | -37.40% | -157.57% | -- | -- | -- |
| EPS Basic | 98.04% | 0.23% | -- | -- | -- |
| Normalized Basic EPS | 96.97% | 23.70% | -- | -- | -- |
| EPS Diluted | 93.24% | -9.16% | -- | -- | -- |
| Normalized Diluted EPS | 96.46% | 22.81% | -- | -- | -- |
| Average Basic Shares Outstanding | 2,571.30% | 210.42% | -- | -- | -- |
| Average Diluted Shares Outstanding | 2,667.41% | 226.79% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |